Alvotech And Sandoz Partner To Launch Biosimilars In Canada, Australia And New Zealand, New Agreements Expand Alvotech’s Biosimilar Footprint

Alvotech announced that it has signed new supply and commercialisation agreements with Sandoz to advance several biosimilar products in Canada and in Australia and New Zealand. The partnerships aim to expand patient access to affordable biologic medicines once regulatory approvals are secured in these markets.

In Canada, the collaboration will focus on a single ophthalmology biosimilar delivered through a prefilled syringe for intravitreal injection. In Australia and New Zealand, the agreement includes three biosimilar candidates in immunology and gastroenterology, offered in multiple formulations. Sandoz will oversee regulatory submissions and commercial rollout in these regions, working closely with Alvotech throughout the process.

“These agreements with Sandoz further advance Alvotech’s strategy of securing commercial pathways for its biosimilars portfolio across global markets ahead of regulatory approval,” said Róbert Wessman, Chairman. “These partnerships reflect the strength of our integrated development and manufacturing platform and our ability to work with experienced regional partners to expand patient access while maintaining capital discipline.”

Under the terms of the agreements, Sandoz will handle marketing, distribution, and regulatory interactions locally, while Alvotech will continue to manage product development, global clinical programs, and manufacturing. Alvotech will also supply finished products to Sandoz through exclusive supply arrangements.

The collaboration builds on Sandoz’s strong footprint in Canada and the Asia-Pacific region and reflects its mission to broaden access to high-quality biosimilars. Together, the companies aim to deliver sustainable and cost-effective biologic therapies to patients following market launch.